The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
A study demonstrated a connection between Epic's CTC-based PD-L1 assessment and patient outcomes, though clinical validation for immunotherapy prediction is still ongoing.
Biocept's Target Selector liquid biopsy platform is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample.
Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries.
The firm's net loss in Q1 was up about 60 percent year over year, but it reported plans to share validation data for its lung cancer test next month.
The firm recently announced that its nanoparticle tagging technology demonstrated higher sensitivity in detecting signs of disease than conventional methods.
Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.
Eleven laboratories that are part of Thermo's OncoNetwork Consortium tested the Oncomine Lung cfDNA assay on reference samples.
Owlstone Medical said that the investment provides validation of its asymmetric ion mobility spectrometry technology for potential use in several cancers.